Basic & Clinical Medicine ›› 2023, Vol. 43 ›› Issue (1): 30-37.doi: 10.16352/j.issn.1001-6325.2023.01.0030

• Invited Reviews: Basic Research and Clinical Translation of Adult Stem Cells • Previous Articles     Next Articles

Progress in application of mesenchymal stem cells in treatment of nephropathy

YANG Yunzhao, SHI Meihan, ZHOU Cheng, BAI Xueyuan*   

  1. Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing 100853, China
  • Received:2022-07-13 Revised:2022-10-10 Published:2022-12-27
  • Contact: *

Abstract: Mesenchymal stem cells (MSCs) can reduce inflammation, restore renal injury and maintain immune homeostasis by paracrine various cytokines and regulating immune cells. In preclinical studies, it has been proved that mesenchymal stem cells have obvious therapeutic effects on acute kidney injury, diabetic nephropathy, lupus nephritis and various glomerular diseases in animal models. In clinical studies, mesenchymal stem cells have also been shown to be safe and partially effective. Mesenchymal stem cell therapy has revealed a new model of biotherapy in kidney diseases.

Key words: mesenchymal stem cells, nephropathy, immune response

CLC Number: